MacroGenics Gets Nod For Margenza In HER2-Positive Breast Cancer

Company Reaches Milestone With First FDA Approval

 
• By Alaric DeArment
  
Doctor with Mammography - Image
MacroGenics won its first FDA approval, for Margenza in HER2-positive breast cancer • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip